{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:36:19Z","timestamp":1778661379581,"version":"3.51.4"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1097\/md.0000000000006979","type":"journal-article","created":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T15:56:57Z","timestamp":1495641417000},"page":"e6979","source":"Crossref","is-referenced-by-count":3,"title":["Atrial fibrillation was changed into sinus bradycardia in a ROS1-positive advanced lung adenocarcinoma patient who achieved durable response to Crizotinib"],"prefix":"10.1097","volume":"96","author":[{"given":"Lan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Juan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-42-20210309","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"R2-42-20210309","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"R3-42-20210309","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J Clin Oncol"},{"key":"R4-42-20210309","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/JTO.0b013e3182570919","article-title":"Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer","volume":"7","author":"Yasuda","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R5-42-20210309","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14740338.2015.1007040","article-title":"A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients","volume":"14","author":"Dikopf","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"R6-42-20210309","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/cncr.28040","article-title":"Heart rate decrease during crizotinib treatment and potential correlation to clinical response","volume":"119","author":"Ou","year":"2013","journal-title":"Cancer"},{"key":"R7-42-20210309","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/1759-7714.12191","article-title":"Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements","volume":"6","author":"Wu","year":"2015","journal-title":"Thorac Cancer"},{"key":"R8-42-20210309","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.lungcan.2013.11.019","article-title":"On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas","volume":"83","author":"Mescam-Mancini","year":"2014","journal-title":"Lung Cancer"},{"key":"R9-42-20210309","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jtho.2016.08.137","article-title":"High prevalence of concomitant oncogene mutations in prospectively identified patients with ROS1-positive metastatic lung cancer","volume":"12","author":"Wiesweg","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R10-42-20210309","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jtho.2017.01.004","article-title":"ROS1 fusions rarely overlap with other oncogenic drivers in non-small cell lung cancer","volume":"12","author":"Lin","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R11-42-20210309","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"key":"R12-42-20210309","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.2014.58.3302","article-title":"Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results from the EUROS1 Cohort","volume":"33","author":"Mazi\u00e8res","year":"2015","journal-title":"J Clin Oncol"},{"key":"R13-42-20210309","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.taap.2013.04.027","article-title":"Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes","volume":"272","author":"Doherty","year":"2013","journal-title":"Toxicol Appl Pharm"},{"key":"R15-42-20210309","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1001\/jama.289.16.2120","article-title":"What clinicians should know about the QT interval","volume":"289","author":"Al-Khatib","year":"2003","journal-title":"JAMA"},{"key":"R16-42-20210309","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.2217\/fon.15.47","article-title":"Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management","volume":"11","author":"Tartarone","year":"2015","journal-title":"Future Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000006979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:50:34Z","timestamp":1620960634000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201705260-00042"}},"subtitle":["A case report and literature review"],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":15,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000006979","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}